Loading...
•
Jun 30, 2024
CervoMed Q2 2024 Earnings Report
Reported second quarter financial results and provided corporate updates.
Key Takeaways
CervoMed reported its financial results for the second quarter ended June 30, 2024, highlighting the completion of enrollment in the RewinD-LB Phase 2b trial and remaining on track to report topline data in December 2024. The company's cash position was strong due to a private placement, providing runway through 2025.
Completed enrollment in RewinD-LB Phase 2b clinical trial in June 2024, with topline data expected in December 2024.
Hosted a virtual key opinion leader event in July 2024, highlighting neflamapimod’s potential for patients with early-stage DLB.
Completed a private placement for up to $149.4 million in April 2024, extending cash runway through 2025.
Added to the Russell 2000® and Russell 3000® Indexes effective July 1, 2024.
CervoMed
CervoMed
CervoMed Revenue by Segment
Revenue by Segment
NIA grant Revenue
CapyFin.com